Squarepoint’s Enveric Biosciences ENVB Stock Holding History

Squarepoint’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	-$27K	–	3252
2021 Q3	$27K	Buy	+1	New	+$19.4K	﹤0.01%	2810

Other funds holding ENVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Squarepoint's ENVB Position: Q4 2021 in Review

Squarepoint sold out of Enveric Biosciences (ENVB) in Q4 2021, closing a stake of 1 share — an estimated $27K sold.

Squarepoint first reported a position in ENVB in Q3 2021 and held it in 1 quarter. The position peaked at $27K in Q3 2021. 26 funds tracked by Wall St. Rank hold ENVB as of Q4 2021.

Squarepoint reported no remaining Enveric Biosciences position as of Q4 2021 after selling out during the quarter.
Squarepoint sold 1 Enveric Biosciences share in Q4 2021, an estimated $27K.
Squarepoint first reported a position in Enveric Biosciences in Q3 2021 and held it in 1 quarter.
Squarepoint's Enveric Biosciences position peaked at $27K in Q3 2021.
26 funds tracked by Wall St. Rank held Enveric Biosciences as of Q4 2021.

Based on Squarepoint's 13F filing for Q4 2021, filed 14 Feb 2022.